Clinical trial Recruiting at 1 site Interventional Ages 18 to 85

Comparing neurostimulator settings for Parkinson's disease treatment

Official title: Aim 3 Particle Swarm Optimization Postural Instability Gait Disorder

Run by University of Minnesota · NCT05934747 · Data updated 2026-11-12

This study is testing two different settings for a brain device to see which one helps people with Parkinson's disease feel better and improve their movement.

Quick facts

Study typeInterventional
Ages18 Years to 85 Years
SexAll
Enrollment30 (estimated)
SponsorUniversity of Minnesota
Academic / other
Locations1 site (Minneapolis, Minnesota)
StatusRecruiting
StartedMarch 19, 2024
Main results expectedJune 1, 2028
Study endsJanuary 5, 2030
Registry record updatedMay 8, 2026
Trial IDNCT05934747 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-85 diagnosed with Parkinson's disease who have undergone bilateral DBS and meet cognitive assessment criteria.

Probably not a fit

Patients with significant gait impairment due to conditions other than Parkinson's disease or those unable to walk in the off-medication, off-stimulation condition may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effects of two different neurostimulator settings on Parkinson's disease symptoms in patients receiving Deep Brain Stimulation (DBS) therapy. The settings are designed to activate distinct neuroanatomical pathways: one from the Globus Pallidus to the Pedunculopontine Nucleus, and the other from the Pedunculopontine Nucleus back to the Globus Pallidus. Participants will be monitored over two weeks to assess clinically relevant outcomes such as activities of daily living and quality of life. The goal is to determine which neurostimulator setting is more effective for addressing postural instability and gait disorders in Parkinson's patients.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies for managing Parkinson's disease symptoms, particularly gait and postural instability.

How similar studies have gone: Similar studies have shown promise in optimizing neurostimulator settings for Parkinson's disease, but this specific approach is novel in its extended observational period.

Who can join: the full rules

Show full inclusion / exclusion criteria
* Diagnosis of Parkinson's Disease
* Bilateral DBS in STN or GP
* At least 3 months after lead implantation
* Montreal Cognitive Assessment (MoCA):

MoCA=23+

OR: If MoCA score is 23 or less, UBACC will be performed to ensure capacity to consent. If UBACC results are unclear, the MacCAT-CR will be performed. Failed or unclear MacCAT-CR results will exclude the study candidate.

* Between 18-85 years of age
* Has undergone pre-operative 7T MRI (as part of protocol #1210M22183 or standard-of-care) and post-operative CT imaging (standard of care).

8.2 Exclusion Criteria:

* Inability to walk in the off-med, off-stimulation condition (even with safety harness)
* Gait impaired significantly by a condition other than PD
* Breaks or shorts in active contacts
* IPG battery nearing end of life (in patients with primary-cell IPGs)
* Females who are nursing or pregnant

Where it's running

  • University of Minnesota
    Minneapolis, Minnesota, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.